American Transplant Congress, Pennsylvania, United States Of America, 2 - 06 May 2015, pp.2010
Conference Paper / Full Text
United States Of America
disorders are associated with high morbidity and mortality in
end-stage renal disease (ESRD).Kidney transplantation is known to
increase the survival of dialysis patients by ameloriating both
systolic and diastolic functions.
aimed to evaluate the role of immunosuppressive (IS) drug regimens on
cardiac functions of kidney transplant recipients (KTRs) one year
after the transplantation.We prospectively evaluated 100 KTRs
immediately before and one year after the operation, using tissue
Doppler echocardiography.A triple IS therapy including Tacrolimus,
Mycophenolate Mofetil (MMF) and Prednisolone was started for all
patients.After 3-6 months Tacrolimus dose was lowered in order to
achieve target serum levels of 3-7 ng/mL in both groups.MMF was
switched to Everolimus with target levels of 4-6 ng/mL, in Group
I(N=50) while Group II(N=50) continued with MPA.
differences in age, gender, dialysis duration, number of HLA
mismatches existed between the groups.The prevalence of diabetic or
hypertensive nephropathy as the etiology of ESRD was similar.Blood
pressure was strictly controlled.Number of acute rejection episodes
was not different in both groups and no graft loss was observed in
either group.Improvement in cardiac parameters including ejection
fraction (EF), left ventricle diastolic diameter (LVDD), posterior
wall thickness (LVPW), left atrium (LA), pulmonary artery systolic
pressure (PASP), left ventricle hypertrophy (LVH) was significant
before and one year after transplantation.Interestingly, when
compared to Group II, ameloriation of all of the parameters
mentioned above was even better in Group I patients.
ameloriation of cardiovascular functions with everolimus may favor
the choice of this drug in kidney transplant recipients.